We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

265 hedge funds and large institutions have $9.21B invested in Nektar Therapeutics in 2017 Q4 according to their latest regulatory filings, with 84 funds opening new positions, 69 increasing their positions, 96 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

475% more call options, than puts

Call options by funds: $183M | Put options by funds: $31.8M

320% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 20

149% more capital invested

Capital invested by funds: $3.69B → $9.21B (+$5.51B)

75% more funds holding in top 10

Funds holding in top 10: 8 → 14 (+6)

31% more funds holding

Funds holding: 203 → 265 (+62)

0.01% less ownership

Funds ownership: 6.56% → 6.56% (-0.01%)

28% less repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 96

Holders
265
Holders Change
+62
Holders Change %
+30.54%
% of All Funds
6.01%
Holding in Top 10
14
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+75%
% of All Funds
0.32%
New
84
Increased
69
Reduced
96
Closed
20
Calls
$183M
Puts
$31.8M
Net Calls
+$151M
Net Calls Change
+$126M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$423M
2
PC
PointState Capital
New York
+$92.5M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$79.7M
4
CAM
Cormorant Asset Management
Massachusetts
+$78.8M
5
PC
Polar Capital
United Kingdom
+$40.1M

Top Sellers

Rank Fund Capital Flow
1
O
OppenheimerFunds
New York
-$401M
2
CCM
Camber Capital Management
Massachusetts
-$72.9M
3
Invesco
Invesco
Georgia
-$65.2M
4
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$52.8M
5
BM
Bridger Management
New York
-$35.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
WEC
251
Winslow Evans & Crocker
Massachusetts
$17.9K – – –
WAM
252
Wealthspire Advisors (Maryland)
Maryland
$16K +$8.87K +15 +750%
QCG
253
Quadrant Capital Group
Ohio
$11K – – –
TWA
254
TCI Wealth Advisors
Arizona
$11K – – –
CHP
255
Cable Hill Partners
Oregon
$11K +$7.69K +13 New
DCM
256
Delpha Capital Management
New York
$10K +$7.1K +12 New
ST
257
Smithfield Trust
Pennsylvania
$7K +$4.73K +8 New
PCM
258
Prelude Capital Management
New York
$6K -$651K -1,100 -99%
ASN
259
Advisory Services Network
Georgia
$6K +$4.14K +7 New
PFBT
260
Parkside Financial Bank & Trust
Missouri
$5K – – –
WWMSC
261
Wagner Wealth Management (South Carolina)
South Carolina
$3K – – –
AssetMark Inc
262
AssetMark Inc
California
$3K +$1.77K +3 New
FMA
263
FNY Managed Accounts
New York
$3K +$2.37K +4 New
FGC
264
Financial Gravity Companies
Texas
$2K +$1.18K +2 New
Walleye Trading
265
Walleye Trading
New York
$1.21K +$504K +852 +172%
PCG
266
Private Capital Group
Connecticut
$24 +$16K +27 New
RCMNY
267
Rubric Capital Management (New York)
New York
– -$23.9M -66,456 Closed
CM
268
Castleark Management
Illinois
– -$5.39M -14,984 Closed
NFA
269
Nationwide Fund Advisors
Ohio
– -$4.32M -11,992 Closed
AA
270
ALPS Advisors
Colorado
– -$3.69M -10,264 Closed
ECM
271
Endurant Capital Management
California
– -$2.62M -7,287 Closed
PAMU
272
Pictet Asset Management (UK)
United Kingdom
– -$1.46M -4,060 Closed
Artisan Partners
273
Artisan Partners
Wisconsin
– -$1.4M -3,887 Closed
NI
274
Numeric Investors
Massachusetts
– -$912K -2,533 Closed
Simplex Trading
275
Simplex Trading
Illinois
– -$1.22M -2,064 Closed
8 9 10
11
12

NKTR Hedge Fund Activity: Q4 2017 in Review

265 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2017, worth a combined $9.21B — up 149% from $3.69B a quarter earlier.

Buyers outnumbered sellers: 84 funds opened new NKTR positions and 20 closed out — a net gain of 64 holders — while 69 added to existing stakes and 96 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $423M. The largest seller was OppenheimerFunds, cutting an estimated $401M.

  • 265 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2017, up from 203 in Q3 2017.
  • Funds reported $9.21B of Nektar Therapeutics stock for Q4 2017, up 149% quarter-over-quarter.
  • 84 funds opened new Nektar Therapeutics positions in Q4 2017 and 20 closed out, a net change of +64 holders.
  • The largest Nektar Therapeutics buyer in Q4 2017 was Fidelity Investments, an estimated $423M added.
  • The largest Nektar Therapeutics seller in Q4 2017 was OppenheimerFunds, an estimated $401M sold.

Based on aggregated 13F filings for Q4 2017.